HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.

Slides:



Advertisements
Similar presentations
Chagas Tests: Development and Standardization
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.
Dr. Kate Templeton SPAIIN –Stirling Overview HIV Infection Tests used in diagnostic labs How to access them Challenges HIV prevention Non –conformity.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Asymptomatic hepatitis C prevalence in anti-HCV positive subjects (population based study) Valentina Liakina, Arida Buivydiene, Saule Brasiskiene, Jonas.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,
Simplifying Laboratory Test Interpretation
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Hepatitis C virus seroprevalence in Russian Federation: results of population based study Preliminary report K.Kyuregyan, N.Soboleva, V.Kichatova, O.Isaeva,
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Hepatitis C Best Practice Guidelines Susan Thompson, RN, MPH September 2009.
F. Kourgia, M. Vini, E. Zervou
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,
HIV Testing CDC power point edited by M. Myers
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Topic : Hepatitis C. Hepatitis C is an infectious disease of liver which is caused by Hepatitis C virus. It causes the inflammation of liver. Initial.
HIV Testing Quality Assurance and Quality Control
Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
Lara Isobel Compston, Daniel Candotti, Jean-Pierre Allain
HCV Diagnosis. Features of Hepatitis C Virus Infection Incubation periodAverage 6-7 weeks Range 2-26 weeks Acute illness (jaundice)Mild (
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Recent, Five-Year HCV Sero-prevalence Trend Among Deceased Organ Donors in California Marek Nowicki 1, Dem Brucal 1, Claudia Chinchila 1, Steven Takemoto.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
Diagnosis of AIDS Dr.T.V.Rao, MD..
E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
GI BLOCK; This practical class is designed and Prepared by: Prof. Samy A. Azer (Medical Education) Dr. Ali Somily (Microbiology) Prof. Abdul Mageed.
Hepatitis C A Growing Problem of Pakistan. Group Members Zoya Imran Mariam Archer Nawal Nawaz Sidra Tul Muntaha.
Module 4: Testing and monitoring. Module 5: Testing and monitoring Module goal To introduce participants to best practice regarding the different tests,
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.
RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.
TESTING FOR HEPATITIS C: TAILORING AN APPROACH FOR YOUR PRACTICE AND YOUR PATIENTS Prepared by: Deborah Graham, MSPH; Elizabeth Horsley, MSJ; & Kim Kimminau,
Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid Stephen R. Lee, Keith W. Kardos, Eugene Schiff,
 Direct  Indirect  Direct: -Microscopy -Culture -Antigen -Nucleic acid  Indirect: -Specific antibody (Serology)
MICROBIOLOGY IRS. Gastroenteritis 1) Major cause of infantile death 2) Feacal-oral transmission 3) Gastroenteritis cause dehydration 4) 50 % of all causes.
Chief, Laboratory of Molecular Virology, CBER, FDA
Abbott HCV core Ag and HCV RNA Comparison Study
Screening Test Kit Name
In The Name of God.
MICROBIOLOGY PRACTICAL
*Dr. Mushtak T. S Al-Ouqaili **Dr. Yasin Hamad Majeed
Laboratory Diagnosis of Infectious Diseases
MICROBIOLOGY PRACTICAL
Case Definition: HEPATITIS C
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Jeffrey J. Germer, BS, Nizar N. Zein, MD  Mayo Clinic Proceedings 
Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections.
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
Guideline 1: Detection and evaluation of HCV in CKD
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol

Overview - diagnostic tests 1.Serologic assays: specific antibody to hepatitis C virus (anti-HCV) 2.Molecular assays: HCV nucleic acid (nucleic acid tests-NAT)

Putative HCV genome including the locations of the HCV encoded antigens and peptides (CHIRON® RIBA® HCV 3.0 SIA)

Overview - serologic tests Enzyme immunoassay (EIA) 1st generation EIA - antibodies to a single epitope NS4 2nd generation EIA – HCV core and nonstructural (NS3 and NS4) proteins. 3rd generation EIA – HCV core and nonstructural (NS3, NS4 and NS5) regions Chemiluminescent assay (CIA) HCV core antigen

Overview - serologic tests Recombinant immunoblot assay (RIBA): Confirmatory test antibodies to HCV core (c22p) Recombinant NS3 (c33c) non-structural regions NS4 (c100p & 5-1-1p) non-structural regions NS5 - Sensitivity 99.5% - Specificity 98.8%

Overview - molecular assays Qualitative assays Quantitative assays

Initial screening test for HCV Assay (EIA or CIA) 98% sensitivity and economical False negative False positive signal-to-cut-off ratio

Confirmatory tests for HCV HCV RIBA test True positive Intermediate HCV RNA tests Qualitative Quantitative very low limit of detection broad dynamic quantitative range across the different HCV gentoypes HCV testing and confirmation in low pretest probability of infection; HCV EIA RIBA

EIA for Anti HCV HCV RNA Negative for HCV infection Additional Testing recommended: Acute HCV suspected Immunocompromised RIBAActive HCV Infection Resolved HCV InfectionFalse Reactive EIA

UPDATE ON HCV KATH BLOOD BANK PROTOCOL Detection of Chronic HCV infection and recovery among a cohort of HCV positive blood donors in Kumasi

Aim:- Pilot study to validate previous assay studies and develop accurate estimates of HCV prevalence and recovery. Objectives : 1.Re-call and re-test previous blood donors at the KATH, to allow re-testing with third generation HCV assays as well as confirmatory RIBA and viral load testing. 2.Compare HCV third generation EIA and RIBA assays results to the previously used HCV rapid screening test results. 3.Develop criteria to define chronic infection and HCV recovery based on assay results that will be used in future studies. 4.Develop an initial cohort of chronically infected and spontaneously recovered subjects.

Methods Participant inclusion: Historic blood donors at KATH ( ) who were HCV screen test positive HCV assays: HCV Third generation EIA, EIA confirmatory test-RIBA, HCV RNA, and viral genotyping (if RNA is detected)

Summary HCV Screen Positive HCV Screen Negative Total Male Female9211 Total442973

THANK YOU